Stay updated on KarXT for Schizophrenia: Long-term Clinical Trial
Sign up to get notified when there's something new on the KarXT for Schizophrenia: Long-term Clinical Trial page.

Latest updates to the KarXT for Schizophrenia: Long-term Clinical Trial page
- Check5 days agoChange DetectedAdded sponsor attribution 'Karuna Therapeutics, Inc., a Bristol Myers Squibb company'. Removed the shorter sponsor name 'Karuna Therapeutics', the disease term 'Schizophrenia', and the related topic 'MedlinePlus Genetics' from the page.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedRevision label updated to v3.5.0; the previous v3.4.3 label was removed.SummaryDifference0.0%

- Check27 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check48 days agoChange DetectedSchizophrenia and MedlinePlus Genetics were removed from the page's related topics. This reduces explicit tagging for the study's condition and related genetics resources, potentially affecting searchability and topic discovery.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded Revision: v3.4.2; Removed the government funding status notice and Revision: v3.4.1 from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now includes a government funding/status notice, new related-topic links (Schizophrenia and MedlinePlus Genetics), and updates the revision tag to v3.4.1, replacing v3.4.0.SummaryDifference0.3%

Stay in the know with updates to KarXT for Schizophrenia: Long-term Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT for Schizophrenia: Long-term Clinical Trial page.